CureVac Overview
- Year Founded
-
2000
- Status
-
Acquired/Merged
- Employees
-
750
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.29B
- Investors
-
1
CureVac General Information
Description
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
Contact Information
Website
www.curevac.comCorporate Office
- Friedrich-Miescher-Strasse 15
- 72076 Tubingen
- Germany
Corporate Office
- Friedrich-Miescher-Strasse 15
- 72076 Tubingen
- Germany
CureVac Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 18. Merger/Acquisition | 18-Dec-2025 | $1.29B | Completed | Generating Revenue | ||
| 17. 2PO | 09-Feb-2023 | Completed | Generating Revenue | |||
| 16. 2PO | 29-Jan-2021 | Completed | Generating Revenue | |||
| 15. PIPE | 14-Aug-2020 | Completed | Generating Revenue | |||
| 14. IPO | 14-Aug-2020 | Completed | Generating Revenue | |||
| 13. Later Stage VC | 21-Jul-2020 | Completed | Generating Revenue | |||
| 12. Debt - General | 27-Jun-2020 | Completed | Generating Revenue | |||
| 11. Grant | 16-Mar-2020 | Completed | Generating Revenue | |||
| 10. Later Stage VC | 18-Oct-2017 | $100M | $1.04B | Completed | Clinical Trials - Phase 2 | |
| 9. Later Stage VC | 08-Nov-2016 | $29.5M | $935M | Completed | Clinical Trials - Phase 1 |
CureVac Comparisons
Industry
Financing
Details
CureVac Competitors (36)
One of CureVac’s 36 competitors is Moderna, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Moderna | Formerly VC-backed | Cambridge, MA | ||||
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Novavax | Corporation | Gaithersburg, MD | ||||
| BioCryst Pharmaceuticals | Corporation | Durham, NC | ||||
| Arcturus Therapeutics Holdings | Formerly VC-backed | San Diego, CA |
CureVac Patents
CureVac Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026234261-A1 | Novel lipid nanoparticle formulations for delivery of nucleic acids, having a piperidine ring and two chains with two carboxyl groups each | Pending | 09-May-2025 | ||
| WO-2026233566-A1 | Optimized rna molecules | Pending | 09-May-2025 | ||
| WO-2026234283-A1 | Optimized rna molecules | Pending | 09-May-2025 | ||
| WO-2025242815-A1 | Immunotherapy of squamous cell carcinoma | Pending | 23-May-2024 | ||
| GB-202404607-D0 | Rna formulation | Inactive | 29-Mar-2024 | A61K9/0019 |
CureVac Signals
CureVac Former Investors (22)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Baden-Württemberg | Government | |||
| Baillie Gifford | Growth/Expansion | Minority | ||
| Boehringer Ingelheim | Corporation | Minority | ||
| Chartwave | Corporation | Minority | ||
| Coppel Family | Other | Minority |
CureVac Acquisitions (1)
CureVac’s most recent deal was a Merger/Acquisition with Frame Therapeutics for . The deal was made on 08-Jun-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Frame Therapeutics | 08-Jun-2022 | Merger/Acquisition | Drug Discovery |
CureVac ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.05 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
CureVac Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Curevac Belgium | Ottignies-Louvain-La-Neuve, Belgium | 2022 | |
| Frame Therapeutics | Amsterdam, Netherlands | 2018 |
CureVac FAQs
-
When was CureVac founded?
CureVac was founded in 2000.
-
Where is CureVac headquartered?
CureVac is headquartered in Tubingen, Germany.
-
What is the size of CureVac?
CureVac has 750 total employees.
-
What industry is CureVac in?
CureVac’s primary industry is Drug Discovery.
-
Is CureVac a private or public company?
CureVac is a Private company.
-
What is the current valuation of CureVac?
The current valuation of CureVac is .
-
What is CureVac’s current revenue?
The current revenue for CureVac is .
-
How much funding has CureVac raised over time?
CureVac has raised $2.78B.
-
Who are CureVac’s investors?
Baden-Württemberg, Baillie Gifford, Boehringer Ingelheim, Chartwave, and Coppel Family are 5 of 22 investors who have invested in CureVac.
-
Who are CureVac’s competitors?
Moderna, Sarepta Therapeutics, Novavax, BioCryst Pharmaceuticals, and Arcturus Therapeutics Holdings are some of the 36 competitors of CureVac.
-
When was CureVac acquired?
CureVac was acquired on 18-Dec-2025.
-
Who acquired CureVac?
CureVac was acquired by BioNTech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process